China's Biotech Supply Chain Advances: How the US Redraws the Safety Borders of the Biomedical Industry

US biotech policy is shifting.

In the past, Washington was concerned with whether Chinese contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), and genomic testing and data services were entering US government supply chains. Today, the issue has expanded to a deeper level: whether Chinese biotech companies are becoming significant sources of global drug innovation, and whether US capital, pharmaceutical out-licensing deals, and clinical data are conversely boosting China's biotech competitiveness.

This is exactly why the Biosecure Act, the COINS Act, and the Biotech Investment National Security Act (BINSA) have emerged. The US no longer treats Chinese biotech merely as low-cost suppliers, but integrates it into discussions surrounding economic security, medical resilience, and industrial sovereignty.

This policy toolkit can be categorized into four distinct layers.

The Biosecure Act governs federal procurement and government-subsidized supply chains; the COINS Act regulates outbound US capital flows; BINSA seeks to include biotech transactions under outbound investment screening; and the US Department of Health and Human Services (HHS) along with the Food and Drug Administration (FDA) push for early-stage clinical trial reforms to make up for the domestic research velocity shortfall.

Washington's policy focus is undergoing a profound mutation. The past priority was mitigating Chinese supplier risks; the current agenda is proactively preventing China from securing US capital, clinical resources, and global commercialization channels. The biotechnology industry is entering an era of securitization.

China's Biotech Pressure Transcends Low-Cost Supply Chains

China’s biotech industry has rapidly upgraded in recent years, and competitive pressure no longer stems solely from inexpensive research services and manufacturing costs. Chinese pharmaceutical firms continue to advance in antibody-drug conjugates (ADCs), multi-specific antibodies, oncology drugs, and early-stage clinical development, while multinational pharmaceutical companies have begun aggressively in-licensing drug assets from China.

Pfizer’s collaboration with Innovent Biologics, valued at up to $10.5 billion, and Bristol Myers Squibb’s transaction with Jiangsu Hengrui Pharmaceuticals, make it increasingly difficult for the US Congress to view Chinese biotech through a conventional commercial lens.

For multinational pharma giants, these deals possess a clear industrial logic. Facing patent cliffs and declining R&D returns, pharmaceutical companies require faster, cheaper, and clinically advanced pipeline reinforcements. The early-stage assets provided by Chinese drugmakers perfectly fulfill this demand.

However, from Congress's perspective, these deals carry long-term strategic risks. As US drugmakers integrate Chinese R&D achievements into their global product pipelines, US capital, market access, clinical design, and commercialization capabilities may act as amplifiers for China's biotech modernization.

China is no longer just a link in the supply chain; it is migrating toward the source of innovation. This is the core background behind the US policy shift.

Biosecure Act: Targeting Government Funding and Supply Chains First

The Biosecure Act represents the first line of defense for the US. This legislation, integrated into the National Defense Authorization Act (NDAA) for Fiscal Year 2026, restricts the US federal government, government contractors, and federal grant recipients from using equipment and services provided by "biotechnology companies of concern" in government contracts or grant-related activities.

It does not outright ban the US private sector from interacting with Chinese biotech firms. Its immediate scope is confined to federal procurement, government contracts, and subsidized funding. However, because the US biotech industry is deeply intertwined with government funding, universities, research institutions, healthcare systems, military medicine, public health initiatives, and drug development firms must re-evaluate their supply chains if they involve any federal funds.

The key to the Biosecure Act lies in its listing mechanism. The Office of Management and Budget (OMB) will establish a "biotechnology companies of concern" list, which is likely to link up with national security tools like the Department of Defense's 1260H "Chinese Military Companies" list. This signifies that it is not a static, one-time ban, but an active supply chain governance framework that updates with political, intelligence, and industrial evaluations.

WuXi AppTec is the most iconic case. The company has long been deeply integrated into the US drug R&D and manufacturing supply chain. If subjected to stricter limits in the future, US pharmaceutical companies, research institutions, and contractors will face the friction of tech transfer, quality validation, manufacturing reconstruction, and delayed development timelines.

The policy signal sent by the Biosecure Act is unambiguous: anyone involving US public funds, military medicine, government procurement, and sensitive healthcare supply chains will face heightened scrutiny when using Chinese biotech service providers.

COINS Act: From Supply Chain Security to Capital Controls

The second layer of the toolkit is the COINS Act. This legislation codifies the US outbound investment security review system, with its current focus on artificial intelligence, semiconductors, microelectronics, and quantum information. While biotechnology is not yet formally included, the Biotech Investment National Security Act (BINSA) proposed in 2026 points directly to the next step: incorporating drug development, biologics manufacturing, and clinical research and development into outbound investment screening.

The significance of the COINS Act is that it pushes the policy question from "Can the US use Chinese services?" to "Can US capital assist China's industrial upgrading?" This differs from the logic of the Biosecure Act. While the Biosecure Act addresses supply chain dependency, the COINS Act targets the outflow of capital, technology, and managerial capabilities.

If biotechnology is incorporated into outbound investment reviews, certain licensing transactions, joint ventures, equity investments, joint development, and clinical collaborations may fall under national security assessments. Transactions might not be outright banned, but reporting costs, review timelines, and boardroom risk will escalate.

This presents a new environment for the biotech sector. The semiconductor industry has long been accustomed to export controls, investment reviews, and end-user restrictions; whereas pharmaceutical and biotech firms have traditionally relied on global clinical trials, multi-center trials, licensing deals, and transnational R&D. Today, the biotech industry is beginning to enter a similar policy pressure cooker.

BINSA: Chinese Drug Out-Licensing Transactions Spark Congressional Alert

BINSA is currently the most critical piece of new legislation to monitor. It advocates for adding biotechnology to the COINS Act review scope, covering drug development, biologics manufacturing, and clinical research and development.

The timing of this bill's appearance is unsurprising. Over the past few years, major US pharmaceutical companies have heavily in-licensed early-stage drug assets from China, placing Chinese developers' R&D outputs into their global pipelines. To drugmakers, this is pipeline management; to certain members of Congress, it looks like US capital and market channels helping Chinese biotechnology establish international competitiveness.

Congressional anxiety stems mainly from three areas:

First, if Chinese drug assets are commercialized globally through US pharmaceutical companies, it enhances the valuation, R&D capabilities, and international visibility of Chinese biotech firms.

Second, low-cost, high-speed early-stage assets from China may crowd out funding opportunities for US startups, particularly in hot fields like oncology, ADCs, and multi-specific antibodies.

Third, clinical data, development processes, and platform technologies may flow bidirectionally during collaboration, making it difficult to separate general commercial cooperation from strategic technology outflow in the future.

If BINSA continues to advance, its most likely outcome is not a blanket ban, but reporting, review, and risk classification. Licensing prices, transaction speeds, partnership structures, and data arrangements for Chinese-origin assets will all be re-priced.

Defensive Measures Are Not Enough: The US Must Accelerate Its Own R&D

If the US only rolls out the Biosecure Act, the COINS Act, and BINSA, its policy remains purely defensive. The challenge is that China’s biotech competitiveness does not rely solely on state policy; it also stems from clinical development speed, patient recruitment efficiency, supply chain integration, and regulatory coordination.

This is why HHS and the FDA are advancing early-stage clinical trial reforms. The directions of reform include rolling Investigational New Drug (IND) submissions, early communications with regulatory agencies, more flexible trial designs, and shortening the lead-time for first-in-human trials. The policy objective is direct: keep more early-stage human clinical trials within the United States.

This reform is vital for the US. If clinical trials in the US are costly, slow to launch, and FDA communication remains volatile, enterprises will naturally seek faster R&D fields. The appeal of China, Australia, and other markets stems partly from institutional speed, not just cost.

To maintain its biotech leadership, the US cannot simply restrict Chinese assets from entering US pipelines. It must also re-establish the US domestic market as a more efficient clinical trial arena. Regulatory stability, patient recruitment, trial costs, data quality, and industrial capital will determine whether companies are willing to keep early-stage development at home.

For Enterprises, Compliance Has Escalated to a Boardroom Agenda

This policy shift will directly alter corporate decision-making. US pharmaceutical companies, biotech startups, venture capital, and research institutions must map out their China-related risks over the next two years:

First, supply chains must be thoroughly audited. CROs, CDMOs, genomic testing, clinical research, reagents, equipment, software, and data processing services involving China or potentially concerned entities must be cataloged.

Second, existing contracts must be reviewed. If collaborations involve federal funds, government procurement, military medicine, or public health programs, the Biosecure Act could influence vendor selection.

Third, licensing transactions must account for national security risks. In-licensing Chinese assets involving joint R&D, platform technologies, clinical data, equity investments, or control arrangements may be subject to review in the future.

Fourth, alternative suppliers must be established early. CDMOs and CROs cannot be replaced overnight; technology transfer, manufacturing validation, quality documentation, and regulatory reviews require substantial time.

Fifth, boards must integrate Sino-US biotech transactions into long-term governance. This is no longer merely a licensing judgment for business development departments, but a comprehensive issue of compliance, national security, reputation, and supply chain resilience.

Pressure for Restructuring on Chinese Biotech Firms

Chinese pharmaceutical firms will also be forced to adapt. In the past, Chinese companies could secure capital, international clinical experience, and global market access through out-licensing deals with US pharma. In the future, if BINSA or related reviews advance, the cost of Chinese assets entering US pharma pipelines will rise.

Three subsequent trends may emerge:

First, Chinese companies will accelerate partnerships with Europe, Japan, the Middle East, and the Global South to reduce dependency on US transactions.

Second, Chinese firms will prioritize domestic clinical development, domestic insurance reimbursement, and independent commercialization, shifting away from purely out-licensing-reliant business models.

Third, high-quality Chinese assets will still enter global markets, but through more complex structures such as regional licensing, data silo isolation, third-country entities, or stricter compliance arrangements.

US regulatory pressure will inject short-term uncertainty into Chinese biotech, but it may also push Chinese firms to accelerate international diversification. If the US cannot simultaneously elevate its own R&D efficiency, controls alone may not prevent the globalization of Chinese biotechnology.

Opportunities for Taiwan and the Asian Biomedical Sector

The US redesign of its biotechnology supply chain will also alter industrial opportunities in Asia. If US pharmaceutical companies reduce reliance on Chinese CROs, CDMOs, and clinical resources, alternative trustworthy hubs in Asia will have opportunities to capture this redirected demand.

Taiwan can position itself strategically in four areas:

First, establish trusted clinical data and patient recruitment capabilities, especially in Asian cohorts, precision medicine, oncology, and rare diseases.

Second, strengthen capabilities in cell and gene therapy, biologics, nucleic acid drugs, and high-specification CDMO services.

Third, establish data governance, cybersecurity, and regulatory quality systems that align with US and EU standards.

Fourth, construct biomedical collaboration networks with Japan, South Korea, Singapore, and Australia to absorb the US de-risking demand.

Taiwan should not view this shift simply as a US-China conflict. It represents an epochal realignment of the global biomedical supply chain. If Taiwan can establish its position with trustworthy clinical standards, regulatory quality, and manufacturing competence, it stands to capture a crucial new role as the US de-risks.

The Securitization Era of the Biotech Industry

The debate at BIO 2026 was ostensibly about whether Chinese drug in-licensing deals should be screened; the deeper question, however, is how the US prevents China's biotechnology supply chain and innovation capacity from undermining its own industrial dominance.

The Biosecure Act severs government supply chains, the COINS Act establishes an outbound investment framework, BINSA seeks to put biotech under capital reviews, and HHS and the FDA accelerate clinical trial reforms. Together, these tools point in the same direction: the US is elevating biotechnology from a conventional pharmaceutical sector to a matter of national competition and economic security.

The success of this policy suite depends on whether the US can execute four tasks simultaneously: reducing dependency on Chinese supply chains, governing high-risk outbound capital, refining early-stage clinical efficiency, and cultivating trusted alternative capacities.

If the US only focuses on defensive restrictions, industrial costs will rise and drug development may slow. If it can bind restriction, review, clinical reform, and domestic supply chain reinforcement into a single cohesive policy, the US will have the opportunity to sustain its global leadership amid the rise of Chinese biotechnology.

The biotech industry has entered the era of securitization. Out-licensing, clinical trials, CDMO selection, and data flows will all become battlegrounds of national competition. This is true for the US, and equally true for Taiwan and the broader Asian biomedical industry.